Liposomes: An emerging carrier for targeting Alzheimer's and Parkinson's diseases

Pandian, Sureshbabu Ram Kumar; Vijayakumar, Kevin Kumar; Murugesan, Sankaranarayanan; Kunjiappan, Selvaraj

doi:10.1016/j.heliyon.2022.e09575

Cited by 21 publications

(15 citation statements)

References 172 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Liposomes are well-known for their biocompatibility; lipid origins can safely circulate to the peripheral organs and can perform noninvasive delivery. Liposomes are being modified with PEG, specific ligands, and peptides such as rabies virus peptides (RVG) which are very specific to target brain diseases like AD, PD, and carcinomas. , A recent study by dos Santos Rodrigues et al developed liposomes by conjugating transferrin and RVG peptide to the surface of liposomes. These liposomes showed a better ability to transfect cells than naked liposomes without any surface modifications.…”

Section: Liposomesmentioning

confidence: 99%

See 1 more Smart Citation

Recent Advances in Nanotherapeutics for Neurological Disorders

Vashist

Manickam

Raymond

et al. 2023

ACS Appl. Bio Mater.

View full text Add to dashboard Cite

Neurological disorders remain a significant health and economic burden worldwide. Addressing the challenges imposed by existing drugs, associated side-effects, and immune responses in neurodegenerative diseases is essential for developing better therapies. The immune activation in a diseased state has complex treatment protocols and results in hurdles for clinical translation. There is an immense need for the development of multifunctional nanotherapeutics with various properties to address the different limitations and immune interactions exhibited by the existing therapeutics. Nanotechnology has proven its potential to improve therapeutic delivery and enhance efficacy. Promising advancements have been made in developing nanotherapies that can be combined with CRISPR/Cas9 or siRNA for a targeted approach with unique potential for clinical translation. Engineering natural exosomes derived from mesenchymal stem cells (MSCs), dendritic cells (DCs), or macrophages to both deliver therapeutics and modulate the immune responses to tumors or in neurodegenerative disease (ND) can allow for targeted personalized therapeutic approaches. In the present review, we summarize and overview the recent advances in nanotherapeutics in addressing the existing treatment limitations and neuroimmune interactions for developing ND therapies and provide insights into the upcoming advancements in nanotechnology-based nanocarriers.

show abstract

Section: Liposomesmentioning

confidence: 99%

“…Liposomes are well-established, clinically proven nanocarriers (Table ) that have been explored for several years . These nanocarriers have shown significant therapeutic potential to treat various neurological disorders.…”

Section: Liposomesmentioning

confidence: 99%

Recent Advances in Nanotherapeutics for Neurological Disorders

Vashist

Manickam

Raymond

et al. 2023

ACS Appl. Bio Mater.

View full text Add to dashboard Cite

show abstract

“…HHE garuneko hesi fisiologikoa da, eta garunaren eta odolhodien arteko substantzien trukaketa kontrolatzen du, molekula gehienak garunera iristea eragotziz [8][9][10]. HHEk iragazkortasun txikia eta selektiboa du, ia molekula handi guztiak eta molekula txikien %98 garunean sartzea oztopatuz [8,11]. Molekula ezberdinek HHE zeharkatzeko duten gaitasuna parametro ezberdinek zehazten dute, hala nola, pisu molekularrak, tamainak, formak, ionizazio-egoerak, lipofiliak eta plasma-proteina loturaren afinitateak [9].…”

Section: Sarreraunclassified

Estrategia terapeutiko berritzaileak Parkinson gaixotasunean: nanopartikulak

Zubelzu,

Razquin,

Vaquero-Rodriguez

et al. 2023

EKAIA

View full text Add to dashboard Cite

Parkinson gaixotasuna (PG) nahasmendu neurodegeneratibo motor ohikoena da, substantia nigra pars compacta-ko (SNc) neurona dopaminergikoen galeragatik eta horrek eragindako mugitzeko desgaitasunagatik bereizten dena. Klinikan gehien erabiltzen diren egungo tratamenduek, hala nola lebodopak, garuneko neurotransmisio dopaminergikoa lehengoratzen dute. Hala ere, tratamendu horiek sintomatikoak baino ez dira, denbora pasa ahala eraginkortasuna galtzen dute eta eragin kaltegarri larriak eragiten dituzte. Eragin kaltegarrietako batzuk administrazio bidearekin lotuta daude; izan ere, aho-bidezko farmakoek hartzaile dopaminergikoen aktibazio ez-jarraitua eragiten dute, tratamenduarekin lotutako asaldura motorren agerpena bultzatuz. Horregatik, tratamendu berritzaileak aurkitzeaz gain, segurtasun-profil hobeak dituzten administrazio-sistema berriak garatzea beharrezkoa da. Hala, azken urteetan nanopartikulen eraginkortasuna aztertzen duten ikerketa desberdinak burutu dira. Izan ere, nanopartikulek hesi hematoentzefalikoa (HHE) erraz zeharkatzeaz gain, farmakoen bioerabilgarritasuna eta eraginkortasuna hobetuz eragin kaltegarriak minimizatzen dituzte. Nanogarraiatzaile organiko eta ez-organiko desberdinak erabiliz, lebodopa, agonista dopaminergikoak edo faktore neurotrofikoak bezalako farmakoen eraginkortasuna aztertu da PG animalia-ereduetan, emaitza itxaropentsuak lortuz. Hala, nanoingeniaritzako partikulak oso tresna erabilgarria dirudite HHE gurutzatuz farmakoak modu seguru, eraginkor eta iraunkorrean emateko, eta beraz, PG bezalako nahasmendu neurologikoak tratatzeko etorkizun handiko estrategian bilaka daitezke.

show abstract

“…In addition to lipid nanodiscs, formulations to combat the effects of AD on astrocytes have also been made using lipid nanotechnology. Targeting brain cells requires non-invasive, biocompatible therapeutic methods, and liposomes are well-suited because of their unique surface functionalization and sustained, selective delivery [ 138 ]. Suesca et al reported that astrocytes have facilitated the uptake of liposome-containing drugs [ 139 ].…”

Section: Novel Therapeutic Strategies To Target Astrocyte Dysfunction...mentioning

confidence: 99%

“…The microvascular endothelium, pericytes, and astrocytes make up the BBB, which in turn blocks the passage of most hazardous substances and larger hydrophilic molecules [ 161 ]. Between 90 and 98% of the brain’s microvasculature and sheaths are made of astrocyte glial cells [ 138 ]. The cellular connections between blood arteries and neural networks are strengthened by astrocytes.…”

Section: Novel Therapeutic Strategies To Target Astrocyte Dysfunction...mentioning

confidence: 99%

Astrocytic MicroRNAs and Transcription Factors in Alzheimer’s Disease and Therapeutic Interventions

Nassar

Kodi

Satarker

et al. 2022

Cells

View full text Add to dashboard Cite

Astrocytes are important for maintaining cholesterol metabolism, glutamate uptake, and neurotransmission. Indeed, inflammatory processes and neurodegeneration contribute to the altered morphology, gene expression, and function of astrocytes. Astrocytes, in collaboration with numerous microRNAs, regulate brain cholesterol levels as well as glutamatergic and inflammatory signaling, all of which contribute to general brain homeostasis. Neural electrical activity, synaptic plasticity processes, learning, and memory are dependent on the astrocyte–neuron crosstalk. Here, we review the involvement of astrocytic microRNAs that potentially regulate cholesterol metabolism, glutamate uptake, and inflammation in Alzheimer’s disease (AD). The interaction between astrocytic microRNAs and long non-coding RNA and transcription factors specific to astrocytes also contributes to the pathogenesis of AD. Thus, astrocytic microRNAs arise as a promising target, as AD conditions are a worldwide public health problem. This review examines novel therapeutic strategies to target astrocyte dysfunction in AD, such as lipid nanodiscs, engineered G protein-coupled receptors, extracellular vesicles, and nanoparticles.

show abstract

Liposomes: An emerging carrier for targeting Alzheimer's and Parkinson's diseases

Cited by 21 publications

References 172 publications

Recent Advances in Nanotherapeutics for Neurological Disorders

Recent Advances in Nanotherapeutics for Neurological Disorders

Estrategia terapeutiko berritzaileak Parkinson gaixotasunean: nanopartikulak

Astrocytic MicroRNAs and Transcription Factors in Alzheimer’s Disease and Therapeutic Interventions

Contact Info

Product

Resources

About